Subsequent studies have consistently shown that high pre-treatment PIV values are associated with diminished survival outcomes in advanced HER2-positive breast cancer, metastatic castration-resistant prostate cancer, advanced gastric cancer treated with ICIs, and resectable esophageal cancer [16-19]. The gene discussed is ERBB2; the disease is gastric cancer.